JP2019508370A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019508370A5 JP2019508370A5 JP2018532465A JP2018532465A JP2019508370A5 JP 2019508370 A5 JP2019508370 A5 JP 2019508370A5 JP 2018532465 A JP2018532465 A JP 2018532465A JP 2018532465 A JP2018532465 A JP 2018532465A JP 2019508370 A5 JP2019508370 A5 JP 2019508370A5
- Authority
- JP
- Japan
- Prior art keywords
- patient
- ccl20
- level
- disease
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100036848 C-C motif chemokine 20 Human genes 0.000 claims description 61
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 claims description 61
- 238000000034 method Methods 0.000 claims description 54
- 108010065637 Interleukin-23 Proteins 0.000 claims description 48
- 102000013264 Interleukin-23 Human genes 0.000 claims description 48
- 229940124829 interleukin-23 Drugs 0.000 claims description 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 22
- 230000001404 mediated effect Effects 0.000 claims description 21
- 239000005557 antagonist Substances 0.000 claims description 18
- 239000000427 antigen Substances 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 239000012634 fragment Substances 0.000 claims description 17
- 238000003018 immunoassay Methods 0.000 claims description 8
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 208000015943 Coeliac disease Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 230000036541 health Effects 0.000 claims description 4
- 201000006417 multiple sclerosis Diseases 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims description 2
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 206010003445 Ascites Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 102100026887 Beta-defensin 103 Human genes 0.000 claims description 2
- 102100026886 Beta-defensin 104 Human genes 0.000 claims description 2
- 102100038326 Beta-defensin 4A Human genes 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 102100025074 C-C chemokine receptor-like 2 Human genes 0.000 claims description 2
- -1 CCL22 Proteins 0.000 claims description 2
- 102100038608 Cathelicidin antimicrobial peptide Human genes 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010012442 Dermatitis contact Diseases 0.000 claims description 2
- 102000002149 Elafin Human genes 0.000 claims description 2
- 108010015972 Elafin Proteins 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 241000700721 Hepatitis B virus Species 0.000 claims description 2
- 101000912247 Homo sapiens Beta-defensin 103 Proteins 0.000 claims description 2
- 101000912243 Homo sapiens Beta-defensin 104 Proteins 0.000 claims description 2
- 101000884714 Homo sapiens Beta-defensin 4A Proteins 0.000 claims description 2
- 101000716068 Homo sapiens C-C chemokine receptor type 6 Proteins 0.000 claims description 2
- 101000741320 Homo sapiens Cathelicidin antimicrobial peptide Proteins 0.000 claims description 2
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 claims description 2
- 101001076418 Homo sapiens Interleukin-1 receptor type 1 Proteins 0.000 claims description 2
- 101000852992 Homo sapiens Interleukin-12 subunit beta Proteins 0.000 claims description 2
- 101000998146 Homo sapiens Interleukin-17A Proteins 0.000 claims description 2
- 101000998151 Homo sapiens Interleukin-17F Proteins 0.000 claims description 2
- 101001010626 Homo sapiens Interleukin-22 Proteins 0.000 claims description 2
- 101000853012 Homo sapiens Interleukin-23 receptor Proteins 0.000 claims description 2
- 101000853000 Homo sapiens Interleukin-26 Proteins 0.000 claims description 2
- 101001023833 Homo sapiens Neutrophil gelatinase-associated lipocalin Proteins 0.000 claims description 2
- 101000642478 Homo sapiens Serpin B3 Proteins 0.000 claims description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 102100037850 Interferon gamma Human genes 0.000 claims description 2
- 108010074328 Interferon-gamma Proteins 0.000 claims description 2
- 102100020881 Interleukin-1 alpha Human genes 0.000 claims description 2
- 102100026016 Interleukin-1 receptor type 1 Human genes 0.000 claims description 2
- 102100036701 Interleukin-12 subunit beta Human genes 0.000 claims description 2
- 102100033461 Interleukin-17A Human genes 0.000 claims description 2
- 102100033454 Interleukin-17F Human genes 0.000 claims description 2
- 102100030704 Interleukin-21 Human genes 0.000 claims description 2
- 102100030703 Interleukin-22 Human genes 0.000 claims description 2
- 102100036672 Interleukin-23 receptor Human genes 0.000 claims description 2
- 102100036679 Interleukin-26 Human genes 0.000 claims description 2
- 102000004889 Interleukin-6 Human genes 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 208000004554 Leishmaniasis Diseases 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 102000001691 Member 3 Group F Nuclear Receptor Subfamily 1 Human genes 0.000 claims description 2
- 108010029279 Member 3 Group F Nuclear Receptor Subfamily 1 Proteins 0.000 claims description 2
- 208000031888 Mycoses Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 102100035405 Neutrophil gelatinase-associated lipocalin Human genes 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 101000912227 Pan troglodytes Beta-defensin 104A Proteins 0.000 claims description 2
- 206010036790 Productive cough Diseases 0.000 claims description 2
- 102100029812 Protein S100-A12 Human genes 0.000 claims description 2
- 102100032446 Protein S100-A7 Human genes 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 108091008773 RAR-related orphan receptors γ Proteins 0.000 claims description 2
- 108010005256 S100 Calcium Binding Protein A7 Proteins 0.000 claims description 2
- 108700016890 S100A12 Proteins 0.000 claims description 2
- 101150097337 S100A12 gene Proteins 0.000 claims description 2
- 102100036383 Serpin B3 Human genes 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 238000011374 additional therapy Methods 0.000 claims description 2
- 208000002029 allergic contact dermatitis Diseases 0.000 claims description 2
- 208000004631 alopecia areata Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 239000000090 biomarker Substances 0.000 claims description 2
- 238000001574 biopsy Methods 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000009266 disease activity Effects 0.000 claims description 2
- MDCUNMLZLNGCQA-HWOAGHQOSA-N elafin Chemical compound N([C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H]2CSSC[C@H]3C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CSSC[C@H]4C(=O)N5CCC[C@H]5C(=O)NCC(=O)N[C@H](C(N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]5N(CCC5)C(=O)[C@H]5N(CCC5)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H](C)NC2=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N4)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N3)=O)[C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(C)C)C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)N MDCUNMLZLNGCQA-HWOAGHQOSA-N 0.000 claims description 2
- 210000002919 epithelial cell Anatomy 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 108010074108 interleukin-21 Proteins 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 230000037361 pathway Effects 0.000 claims description 2
- 210000002381 plasma Anatomy 0.000 claims description 2
- 210000004910 pleural fluid Anatomy 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 210000003802 sputum Anatomy 0.000 claims description 2
- 208000024794 sputum Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 210000001179 synovial fluid Anatomy 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 229960003824 ustekinumab Drugs 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000005228 Pericardial Effusion Diseases 0.000 claims 1
- 206010037575 Pustular psoriasis Diseases 0.000 claims 1
- 208000025747 Rheumatic disease Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004912 pericardial fluid Anatomy 0.000 claims 1
- 201000010914 pustulosis of palm and sole Diseases 0.000 claims 1
- 208000011797 pustulosis palmaris et plantaris Diseases 0.000 claims 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021172872A JP2022031643A (ja) | 2015-12-22 | 2021-10-22 | Ｉｌ２３アンタゴニストに対する臨床応答の予測因子としてのｃｃｌ２０ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562271156P | 2015-12-22 | 2015-12-22 | |
| US62/271,156 | 2015-12-22 | ||
| PCT/US2016/067120 WO2017112536A1 (en) | 2015-12-22 | 2016-12-16 | Ccl20 as a predictor of clinical response to il23-antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021172872A Division JP2022031643A (ja) | 2015-12-22 | 2021-10-22 | Ｉｌ２３アンタゴニストに対する臨床応答の予測因子としてのｃｃｌ２０ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019508370A JP2019508370A (ja) | 2019-03-28 |
| JP2019508370A5 true JP2019508370A5 (enExample) | 2020-06-25 |
Family
ID=59091179
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018532465A Pending JP2019508370A (ja) | 2015-12-22 | 2016-12-16 | Ｉｌ２３アンタゴニストに対する臨床応答の予測因子としてのｃｃｌ２０ |
| JP2021172872A Pending JP2022031643A (ja) | 2015-12-22 | 2021-10-22 | Ｉｌ２３アンタゴニストに対する臨床応答の予測因子としてのｃｃｌ２０ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021172872A Pending JP2022031643A (ja) | 2015-12-22 | 2021-10-22 | Ｉｌ２３アンタゴニストに対する臨床応答の予測因子としてのｃｃｌ２０ |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11220541B2 (enExample) |
| EP (1) | EP3393515A4 (enExample) |
| JP (2) | JP2019508370A (enExample) |
| KR (1) | KR20180096633A (enExample) |
| CN (1) | CN108472367A (enExample) |
| AU (1) | AU2016379157A1 (enExample) |
| BR (1) | BR112018012626A2 (enExample) |
| CA (1) | CA3007098A1 (enExample) |
| IL (1) | IL259704A (enExample) |
| MX (1) | MX2018007589A (enExample) |
| RU (1) | RU2018124603A (enExample) |
| WO (1) | WO2017112536A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| CA2998349A1 (en) | 2015-09-17 | 2017-03-23 | Amgen Inc. | Prediction of clinical response to il23-antagonists using il23 pathway biomarkers |
| KR20210064315A (ko) * | 2018-09-24 | 2021-06-02 | 얀센 바이오테크 인코포레이티드 | 항-il12/il23 항체로 궤양성 결장염을 치료하는 안전하고 효과적인 방법 |
| CN108957014A (zh) * | 2018-09-27 | 2018-12-07 | 郑州大学第附属医院 | 结直肠癌血清标志物、表达评估方法、试剂盒及应用 |
| CN113710316A (zh) * | 2019-03-26 | 2021-11-26 | 阿斯特捷利康合作创业有限责任公司 | 适合于il23拮抗剂疗法的患者群体 |
| AU2021385427A1 (en) | 2020-11-30 | 2023-06-29 | Mindera Corporation | Microneedle devices and methods, and skin condition assays |
| CN113092652B (zh) * | 2021-03-19 | 2022-09-30 | 浙江工商大学 | 一种用于评估个体过敏程度的试剂盒 |
| CN114113630B (zh) * | 2021-11-24 | 2023-07-28 | 中南大学湘雅医院 | Serpinb3/b4作为靶点在玫瑰痤疮等炎症性皮肤病治疗药物中的应用 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8318754D0 (en) | 1983-07-11 | 1983-08-10 | Fagerhol M K F | Human proteins anti-sera test kits |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US5455160A (en) | 1993-05-27 | 1995-10-03 | Fagerhol; Magne K. | Diagnostic test and kit for disease or disorders in the digestive system |
| DK0937259T3 (da) | 1996-11-01 | 2005-01-31 | Magne K Fagerhol | Fremgangsmåde til ekstraktion af proteiner |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| CO4810232A1 (es) | 1997-07-25 | 1999-06-30 | Schering Corp | Citoquinas de mamiferos y sus secuencias codificadoras |
| AU2005220910A1 (en) | 2004-03-05 | 2005-09-22 | Archemix Corp. | Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics |
| WO2005107793A2 (en) | 2004-05-06 | 2005-11-17 | The Trustees Of Columbia University | Ngal for reduction and amelioration of ischemic and nephrotoxic injuries |
| KR100681763B1 (ko) | 2005-02-28 | 2007-02-15 | 재단법인 목암생명공학연구소 | 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법 |
| EP3501537A1 (en) | 2005-06-30 | 2019-06-26 | Janssen Biotech, Inc. | Anti-il23 antibodies, compositions, methods and uses |
| EP1937721B1 (en) | 2005-08-25 | 2010-07-28 | Eli Lilly And Company | Anti-il-23 antibodies |
| HUE032131T2 (en) | 2005-08-31 | 2017-09-28 | Merck Sharp & Dohme | Constructed anti-IL-23 antibodies |
| NZ621483A (en) | 2005-12-02 | 2015-10-30 | Genentech Inc | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r |
| DK2548577T3 (en) | 2005-12-29 | 2017-03-13 | Janssen Biotech Inc | HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, PROCEDURES AND APPLICATIONS |
| WO2007098065A2 (en) | 2006-02-17 | 2007-08-30 | The United States Of America As Represented By The Department Of Veterans Affairs | Human sodium channel isoforms |
| JP2009540018A (ja) | 2006-06-13 | 2009-11-19 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法 |
| ATE554791T1 (de) | 2007-02-23 | 2012-05-15 | Schering Corp | Gentechnisch hergestellte anti-il-23p19- antikörper |
| CN103396489A (zh) | 2007-02-23 | 2013-11-20 | 默沙东公司 | 工程改造的抗IL-23p19抗体 |
| AR068723A1 (es) | 2007-10-05 | 2009-12-02 | Glaxo Group Ltd | Proteina que se une a antigenos que se une a il-23 humana y sus usos |
| WO2009082624A2 (en) | 2007-12-10 | 2009-07-02 | Zymogenetics, Inc. | Antagonists of il-17a, il-17f, and il-23 and methods of using the same |
| WO2009114756A2 (en) | 2008-03-14 | 2009-09-17 | Exagen Diagnostics, Inc. | Biomarkers for inflammatory bowel disease and irritable bowel syndrome |
| CA2734919C (en) | 2008-08-27 | 2016-08-16 | Schering Corporation | Lyophilized formulations of engineered anti-il-23p19 antibodies |
| US20100221752A2 (en) | 2008-10-06 | 2010-09-02 | Somalogic, Inc. | Ovarian Cancer Biomarkers and Uses Thereof |
| EP2347256A4 (en) | 2008-10-09 | 2012-02-08 | Alfagene Bioscience Inc | USE AND IDENTIFY BIOMARKERS FOR STOMACH DISEASES |
| US20110212104A1 (en) * | 2008-11-03 | 2011-09-01 | Schering Corporation | Inflammatory bowel disease biomarkers and related methods of treatment |
| US20120128689A1 (en) | 2009-04-01 | 2012-05-24 | Glaxo Group Limited | Anti-il-23 immunoglobulins |
| WO2010129964A1 (en) | 2009-05-08 | 2010-11-11 | The Board Of Trustees Of The University Of Illinois | Drug targets for prevention of arrhythmia in heart disease |
| WO2010142534A1 (en) | 2009-05-27 | 2010-12-16 | Ablynx Nv | Biparatopic protein constructs directed against il-23 |
| AU2010266028B2 (en) | 2009-06-25 | 2015-04-30 | Société des Produits Nestlé S.A. | Methods for diagnosing irritable bowel syndrome |
| JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
| CA2781654A1 (en) | 2009-11-25 | 2011-06-03 | Hua Gong | Novel genomic biomarkers for irritable bowel syndrome diagnosis |
| EA031209B9 (ru) | 2010-01-15 | 2021-11-19 | Кирин-Эмджен, Инк. | Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения |
| JP5972871B2 (ja) | 2010-07-20 | 2016-08-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | 抗ｉｌ−２３ヘテロ二量体特異的抗体 |
| US8541180B1 (en) | 2010-10-11 | 2013-09-24 | Genova Diagnostics, Inc. | Compositions and methods for assessing gastrointestinal health |
| PL2635601T3 (pl) | 2010-11-04 | 2017-02-28 | Boehringer Ingelheim International Gmbh | Przeciwciała anty-il-23 |
| CA2824419A1 (en) | 2011-01-06 | 2012-07-12 | The United States Government As Represented By The Department Of Veteran S Affairs | Scn5a splice variants for use in methods relating to sudden cardiac death and need for implanted cardiac defibrillators |
| WO2012158831A1 (en) | 2011-05-16 | 2012-11-22 | Prometheus Laboratories Inc. | Performance of a biomarker panel for irritable bowel syndrome |
| NO20110895A1 (no) | 2011-06-21 | 2012-12-24 | Magne Fagerhol | Kompetitive S100A9 immunoanalyser |
| NO336551B1 (no) | 2011-06-21 | 2015-09-28 | Magne Fagerhol | Forbedret ELISA for kalprotektin i fekalprøve eller gastrointestinaltraktsprøve |
| WO2013132338A2 (en) | 2012-03-06 | 2013-09-12 | Calpro As | Competitive immunoassay for calprotectin |
| WO2013132347A2 (en) | 2012-03-06 | 2013-09-12 | Calpro As | Improved elisa immunoassay for calprotectin |
| WO2013152114A1 (en) | 2012-04-03 | 2013-10-10 | The Regents Of The University Of Michigan | Biomarker associated with irritable bowel syndrome and crohn's disease |
-
2016
- 2016-12-16 RU RU2018124603A patent/RU2018124603A/ru not_active Application Discontinuation
- 2016-12-16 JP JP2018532465A patent/JP2019508370A/ja active Pending
- 2016-12-16 MX MX2018007589A patent/MX2018007589A/es unknown
- 2016-12-16 CA CA3007098A patent/CA3007098A1/en not_active Abandoned
- 2016-12-16 AU AU2016379157A patent/AU2016379157A1/en not_active Abandoned
- 2016-12-16 BR BR112018012626A patent/BR112018012626A2/pt not_active Application Discontinuation
- 2016-12-16 KR KR1020187017346A patent/KR20180096633A/ko not_active Withdrawn
- 2016-12-16 EP EP16879907.0A patent/EP3393515A4/en not_active Withdrawn
- 2016-12-16 WO PCT/US2016/067120 patent/WO2017112536A1/en not_active Ceased
- 2016-12-16 CN CN201680075323.4A patent/CN108472367A/zh active Pending
- 2016-12-16 US US16/063,803 patent/US11220541B2/en active Active
-
2018
- 2018-05-30 IL IL259704A patent/IL259704A/en unknown
-
2021
- 2021-10-22 JP JP2021172872A patent/JP2022031643A/ja active Pending
- 2021-11-29 US US17/536,663 patent/US20220144935A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018535394A5 (enExample) | ||
| JP2019508370A5 (enExample) | ||
| RU2018113694A (ru) | Прогноз клинического ответа на антагонисты ил-23 с использованием биомаркеров сигнального пути ил-23 | |
| Jena et al. | Response to SARS-CoV-2 vaccination in immune mediated inflammatory diseases: systematic review and meta-analysis | |
| RU2018124603A (ru) | Ccl20 как прогностический фактор клинического ответа на антагонисты ил-23 | |
| US8828668B2 (en) | Markers for determination of patient responsiveness | |
| Shen et al. | Increased serum amyloid A and its association with autoantibodies, acute phase reactants and disease activity in patients with rheumatoid arthritis | |
| Ha et al. | Usefulness of serum leucine-rich alpha-2 glycoprotein as a disease activity biomarker in patients with rheumatoid arthritis | |
| Ming et al. | Elevated TGF-β1/IL-31 pathway is associated with the disease severity of hepatitis B virus–related liver cirrhosis | |
| JP6648023B2 (ja) | 結核のバイオマーカー | |
| Majeed et al. | Serum profiles of pro-inflammatory and anti-inflammatory cytokines in non-hospitalized patients with mild/moderate COVID-19 infection. | |
| TWI655433B (zh) | 川崎氏症之診斷與治療 | |
| Chen et al. | Presence of hepatitis B virus in synovium and its clinical significance in rheumatoid arthritis | |
| EP3077818B1 (en) | Methods for predicting post-operative recurrence of crohn's disease | |
| Pisani et al. | Proteomic insights on the metabolism in inflammatory bowel disease | |
| Fouladseresht et al. | Anti-varicella zoster virus IgG and hsCRP levels correlate with progression of coronary artery atherosclerosis | |
| Viana et al. | Autoantibodies in patients with psoriatic arthritis on anti-TNFα therapy | |
| JP2025533470A (ja) | Ｈｂｖの診断、予後判定及び治療の方法並びに製品 | |
| Gong et al. | Serum progranulin levels are elevated in patients with chronic hepatitis B virus infection, reflecting viral load | |
| Lian et al. | Serum levels of preS antigen (HBpreSAg) in chronic hepatitis B virus infected patients | |
| TWI502199B (zh) | 腫瘤壞死因子受體相關因子７作爲紅斑性狼瘡的生物標記物之用途、偵測人體患有紅斑性狼瘡的方法以及偵測人體患有紅斑性狼瘡的套組 | |
| Ra et al. | Kinetics of Serological Response in Patients with Severe Fever with Thrombocytopenia Syndrome. Viruses 2021, 13, 6 | |
| Kelvin | Ethan B. Jansen, Ali Toloue Ostadgavahi 3, Benjamin Hewins 3, Rachelle Buchanan, Brittany M. Thivierge, Gustavo Sganzerla Martinez 3, Una Goncin 4, Magen E. Francis, Cynthia L. Swan, Erin Scruten, Jack Bell, Joseph Darbellay, Antonio Facciuolo, Darryl Falzarano, Volker Gerdts, Mark E. Fenton 6, Peter Hedlin 4, David J. Kelvin 3 & | |
| Saker et al. | Critical COVID-19 unveils the link between viral particle blood dissemination and prolonged Type I Interferon | |
| Dawood et al. | Assessment Association between IFN-β2, AST and Natural Course of Infections with Hepatitis A and C Viruses |